Taken together, our results expanded our knowledge of the regulatory network between E2Fs and EZH2 in AML and confirmed that E2F4 functions as a tumour suppressor in AML via inhibition of the MAPK signalling pathway by binding to EZH2. This evidence concerns the gene EZH2 and neoplasm.